Adverse events were observed in 15 (42.9%) subjects, nine with transient and mild alanine aminotransferase increases, two with gastrointestinal discomfort, one with mild folliculitis, one with urticaria, one with dizziness, and one with headache (all CTCAE grade 1). This evidence concerns the gene GPT and folliculitis.